JP2020073566A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020073566A5 JP2020073566A5 JP2020002555A JP2020002555A JP2020073566A5 JP 2020073566 A5 JP2020073566 A5 JP 2020073566A5 JP 2020002555 A JP2020002555 A JP 2020002555A JP 2020002555 A JP2020002555 A JP 2020002555A JP 2020073566 A5 JP2020073566 A5 JP 2020073566A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical formulation
- pharmaceutical
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 15
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- FCTRVTQZOUKUIV-MCDZGGTQSA-M potassium;[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound [K+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O FCTRVTQZOUKUIV-MCDZGGTQSA-M 0.000 claims 8
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical group CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 7
- 229960004042 diazoxide Drugs 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 206010020710 Hyperphagia Diseases 0.000 claims 4
- 235000020830 overeating Nutrition 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 102000002265 Human Growth Hormone Human genes 0.000 claims 3
- 108010000521 Human Growth Hormone Proteins 0.000 claims 3
- 239000000854 Human Growth Hormone Substances 0.000 claims 3
- YLLWQNAEYILHLV-UHFFFAOYSA-N 7-chloro-3-methyl-1$l^{6},2,4-benzothiadiazin-2-ide 1,1-dioxide;2-hydroxyethyl(trimethyl)azanium Chemical group C[N+](C)(C)CCO.C1=C(Cl)C=C2S(=O)(=O)[N-]C(C)=NC2=C1 YLLWQNAEYILHLV-UHFFFAOYSA-N 0.000 claims 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000001934 delay Effects 0.000 claims 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021160423A JP7232300B2 (ja) | 2014-11-14 | 2021-09-30 | プラダー－ウィリ症候群またはスミス－マゲニス症候群を有する対象を処置するための方法 |
| JP2023023047A JP7645913B2 (ja) | 2014-11-14 | 2023-02-17 | プラダー－ウィリ症候群またはスミス－マゲニス症候群を有する対象を処置するための方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462080150P | 2014-11-14 | 2014-11-14 | |
| US62/080,150 | 2014-11-14 | ||
| US201562138245P | 2015-03-25 | 2015-03-25 | |
| US62/138,245 | 2015-03-25 | ||
| US201562170035P | 2015-06-02 | 2015-06-02 | |
| US62/170,035 | 2015-06-02 | ||
| US201562221359P | 2015-09-21 | 2015-09-21 | |
| US62/221,359 | 2015-09-21 | ||
| JP2017544842A JP6709226B2 (ja) | 2014-11-14 | 2015-11-12 | プラダー−ウィリ症候群またはスミス−マゲニス症候群を有する対象を処置するための方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544842A Division JP6709226B2 (ja) | 2014-11-14 | 2015-11-12 | プラダー−ウィリ症候群またはスミス−マゲニス症候群を有する対象を処置するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021160423A Division JP7232300B2 (ja) | 2014-11-14 | 2021-09-30 | プラダー－ウィリ症候群またはスミス－マゲニス症候群を有する対象を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020073566A JP2020073566A (ja) | 2020-05-14 |
| JP2020073566A5 true JP2020073566A5 (enExample) | 2020-08-13 |
| JP6955039B2 JP6955039B2 (ja) | 2021-10-27 |
Family
ID=55955075
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544842A Active JP6709226B2 (ja) | 2014-11-14 | 2015-11-12 | プラダー−ウィリ症候群またはスミス−マゲニス症候群を有する対象を処置するための方法 |
| JP2020002555A Active JP6955039B2 (ja) | 2014-11-14 | 2020-01-10 | プラダー−ウィリ症候群またはスミス−マゲニス症候群を有する対象を処置するための方法 |
| JP2021160423A Active JP7232300B2 (ja) | 2014-11-14 | 2021-09-30 | プラダー－ウィリ症候群またはスミス－マゲニス症候群を有する対象を処置するための方法 |
| JP2023023047A Active JP7645913B2 (ja) | 2014-11-14 | 2023-02-17 | プラダー－ウィリ症候群またはスミス－マゲニス症候群を有する対象を処置するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544842A Active JP6709226B2 (ja) | 2014-11-14 | 2015-11-12 | プラダー−ウィリ症候群またはスミス−マゲニス症候群を有する対象を処置するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021160423A Active JP7232300B2 (ja) | 2014-11-14 | 2021-09-30 | プラダー－ウィリ症候群またはスミス－マゲニス症候群を有する対象を処置するための方法 |
| JP2023023047A Active JP7645913B2 (ja) | 2014-11-14 | 2023-02-17 | プラダー－ウィリ症候群またはスミス－マゲニス症候群を有する対象を処置するための方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (8) | US10058557B2 (enExample) |
| EP (1) | EP3217963B1 (enExample) |
| JP (4) | JP6709226B2 (enExample) |
| KR (4) | KR102517840B1 (enExample) |
| CN (3) | CN107106500B (enExample) |
| AU (2) | AU2015346196B2 (enExample) |
| BR (1) | BR112017009986A2 (enExample) |
| CA (4) | CA3125839C (enExample) |
| DK (1) | DK3217963T3 (enExample) |
| EA (1) | EA036103B1 (enExample) |
| ES (1) | ES2806977T3 (enExample) |
| HU (1) | HUE050895T2 (enExample) |
| IL (1) | IL252111B (enExample) |
| MX (2) | MX381305B (enExample) |
| MY (1) | MY187610A (enExample) |
| NZ (1) | NZ768958A (enExample) |
| PL (1) | PL3217963T3 (enExample) |
| SG (1) | SG11201703721SA (enExample) |
| WO (1) | WO2016077629A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104958270A (zh) | 2004-08-25 | 2015-10-07 | 伊森舍丽斯有限公司 | 钾atp通道开放剂的药物制剂及其应用 |
| US9757384B2 (en) | 2005-04-06 | 2017-09-12 | Essentialis, Inc. | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome |
| PL1968601T3 (pl) | 2006-01-05 | 2012-03-30 | Essentialis Inc | Sole związków otwierających kanały potasowe ATP i ich zastosowanie |
| JP6709226B2 (ja) | 2014-11-14 | 2020-06-10 | エッセンシャライズ インコーポレイテッド | プラダー−ウィリ症候群またはスミス−マゲニス症候群を有する対象を処置するための方法 |
| CN109562092B (zh) * | 2016-06-03 | 2023-08-22 | 纽约市哥伦比亚大学理事会 | 治疗普拉德-威利综合症的方法 |
| US11382881B2 (en) | 2017-05-05 | 2022-07-12 | Nino Sorgente | Methods and compositions for diagnosing and treating glaucoma |
| WO2018204721A1 (en) | 2017-05-05 | 2018-11-08 | Nino Sorgente | Methods and compositions for improving eye health |
| US20200093884A1 (en) * | 2018-09-20 | 2020-03-26 | Mark C. Manning | Stable intranasal formulations of carbetocin |
| CN111888330B (zh) * | 2020-09-18 | 2022-08-16 | 常州市第四制药厂有限公司 | 一种二氮嗪口服混悬溶液及制备方法 |
| AU2023365206A1 (en) * | 2022-10-18 | 2025-04-24 | Rhythm Pharmaceuticals, Inc. | Novel atp-sensitive potassium channel potentiators, their preparation and use |
| AU2024341097A1 (en) * | 2023-09-15 | 2026-04-23 | Soleno Therapeutics, Inc. | Methods of managing glycemic control in prader-willi syndrome patients |
| WO2025222188A1 (en) * | 2024-04-18 | 2025-10-23 | Rhythm Pharmaceuticals, Inc. | Novel potassium channel opener compounds and related uses |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2986573A (en) | 1961-01-18 | 1961-05-30 | Schering Corp | Method for the treatment of hypertension |
| GB8601204D0 (en) | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
| GB2186485B (en) | 1986-02-13 | 1988-09-07 | Ethical Pharma Ltd | Slow release formulation |
| US5284845A (en) | 1991-03-14 | 1994-02-08 | Paulsen Elsa P | Use of oral diazoxide for the treatment of disorders in glucose metabolism |
| US5629045A (en) | 1992-09-17 | 1997-05-13 | Richard L. Veech | Biodegradable nosiogenic agents for control of non-vertebrate pests |
| US5399359A (en) | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
| FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
| US6225310B1 (en) * | 1996-01-17 | 2001-05-01 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| WO1998010786A2 (en) | 1996-09-12 | 1998-03-19 | Yarom Cohen | Pharmaceutical composition for the treatment of syndrome x of reaven |
| US6197765B1 (en) | 1999-06-08 | 2001-03-06 | Pnina Vardi | Use of diazoxide for the treatment of metabolic syndrome and diabetes complications |
| AU2001265840A1 (en) | 2000-06-26 | 2002-01-08 | Novo-Nordisk A/S | Use of potassium channel agonists for reducing fat food comsumption |
| TW478039B (en) | 2001-04-09 | 2002-03-01 | Promos Technologies Inc | Phase shift alignment system |
| US6669955B2 (en) | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| US6960346B2 (en) | 2002-05-09 | 2005-11-01 | University Of Tennessee Research Foundation | Vehicles for delivery of biologically active substances |
| US20040143213A1 (en) | 2002-11-12 | 2004-07-22 | Collegium Pharmaceutical, Inc. | Inertial drug delivery system |
| US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
| AU2005256675A1 (en) * | 2004-06-23 | 2006-01-05 | Neurotec Pharma, S.L. | Compounds for the treatment of inflammation of the central nervous system |
| CN104958270A (zh) * | 2004-08-25 | 2015-10-07 | 伊森舍丽斯有限公司 | 钾atp通道开放剂的药物制剂及其应用 |
| CN101043879A (zh) * | 2004-08-25 | 2007-09-26 | 伊森舍丽斯有限公司 | 钾atp通道开放剂的药物制剂及其应用 |
| MX2007004889A (es) * | 2004-10-25 | 2007-09-11 | Solvay Pharm Gmbh | Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados. |
| US9757384B2 (en) | 2005-04-06 | 2017-09-12 | Essentialis, Inc. | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome |
| CN101257897A (zh) * | 2005-07-07 | 2008-09-03 | 西特里斯药业公司 | 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物 |
| PL1968601T3 (pl) | 2006-01-05 | 2012-03-30 | Essentialis Inc | Sole związków otwierających kanały potasowe ATP i ich zastosowanie |
| US20070293552A1 (en) * | 2006-06-15 | 2007-12-20 | Gorczynski Richard J | Antihypertensive therapy method |
| US20120238554A1 (en) | 2007-07-02 | 2012-09-20 | Cowen Neil M | Salts of potassium atp channel openers and uses thereof |
| JP2010532383A (ja) | 2007-07-02 | 2010-10-07 | エッセンシャリス，インク． | カリウムａｔｐチャネル開口薬の塩およびその使用 |
| US20120053172A1 (en) * | 2009-02-12 | 2012-03-01 | Cooperatieve Mirzorg U.A. | Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders |
| RS58237B1 (sr) * | 2011-12-15 | 2019-03-29 | Millendo Therapeutics Sas | Fragmenti neacilovanog grelina za upotrebu u lečenju prader-willi sindroma |
| EP2819675A4 (en) | 2012-02-27 | 2015-07-22 | Essentialis Inc | SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF |
| JP2014074004A (ja) * | 2012-10-05 | 2014-04-24 | Shinichi Niijima | 精神症状の改善剤 |
| WO2014197753A1 (en) | 2013-06-08 | 2014-12-11 | Sedogen, Llc | Method of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia |
| JP6709226B2 (ja) | 2014-11-14 | 2020-06-10 | エッセンシャライズ インコーポレイテッド | プラダー−ウィリ症候群またはスミス−マゲニス症候群を有する対象を処置するための方法 |
-
2015
- 2015-11-12 JP JP2017544842A patent/JP6709226B2/ja active Active
- 2015-11-12 KR KR1020227029800A patent/KR102517840B1/ko active Active
- 2015-11-12 CN CN201580072525.9A patent/CN107106500B/zh active Active
- 2015-11-12 CA CA3125839A patent/CA3125839C/en active Active
- 2015-11-12 DK DK15859169.3T patent/DK3217963T3/da active
- 2015-11-12 NZ NZ768958A patent/NZ768958A/en unknown
- 2015-11-12 CN CN202110786768.6A patent/CN113599386B/zh active Active
- 2015-11-12 KR KR1020177016089A patent/KR102323613B1/ko active Active
- 2015-11-12 BR BR112017009986-1A patent/BR112017009986A2/pt not_active Application Discontinuation
- 2015-11-12 PL PL15859169T patent/PL3217963T3/pl unknown
- 2015-11-12 CA CA3210794A patent/CA3210794A1/en active Pending
- 2015-11-12 CN CN202511504739.0A patent/CN121910740A/zh active Pending
- 2015-11-12 EA EA201791067A patent/EA036103B1/ru unknown
- 2015-11-12 MY MYPI2017701659A patent/MY187610A/en unknown
- 2015-11-12 ES ES15859169T patent/ES2806977T3/es active Active
- 2015-11-12 MX MX2017006244A patent/MX381305B/es unknown
- 2015-11-12 WO PCT/US2015/060455 patent/WO2016077629A1/en not_active Ceased
- 2015-11-12 CA CA2966907A patent/CA2966907C/en active Active
- 2015-11-12 CA CA3125835A patent/CA3125835C/en active Active
- 2015-11-12 AU AU2015346196A patent/AU2015346196B2/en active Active
- 2015-11-12 KR KR1020237010935A patent/KR102598666B1/ko active Active
- 2015-11-12 EP EP15859169.3A patent/EP3217963B1/en active Active
- 2015-11-12 SG SG11201703721SA patent/SG11201703721SA/en unknown
- 2015-11-12 HU HUE15859169A patent/HUE050895T2/hu unknown
- 2015-11-12 KR KR1020217035884A patent/KR102452254B1/ko active Active
- 2015-11-12 MX MX2021003982A patent/MX393030B/es unknown
-
2017
- 2017-05-04 IL IL252111A patent/IL252111B/en unknown
- 2017-08-08 US US15/671,792 patent/US10058557B2/en active Active
-
2018
- 2018-07-20 US US16/041,237 patent/US10456408B2/en active Active
-
2019
- 2019-04-25 AU AU2019202906A patent/AU2019202906B2/en active Active
- 2019-09-17 US US16/573,965 patent/US10874676B2/en active Active
-
2020
- 2020-01-10 JP JP2020002555A patent/JP6955039B2/ja active Active
- 2020-11-25 US US17/104,433 patent/US20210322434A1/en not_active Abandoned
-
2021
- 2021-09-30 JP JP2021160423A patent/JP7232300B2/ja active Active
-
2023
- 2023-02-17 JP JP2023023047A patent/JP7645913B2/ja active Active
-
2024
- 2024-01-24 US US18/421,914 patent/US12109216B2/en active Active
- 2024-09-04 US US18/824,811 patent/US12178823B1/en active Active
- 2024-12-19 US US18/988,636 patent/US12343348B2/en active Active
-
2025
- 2025-05-30 US US19/224,580 patent/US12419895B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021193148A5 (enExample) | ||
| EP1089726B1 (en) | Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid | |
| JP2017533972A5 (enExample) | ||
| AU2023204000A1 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| JP2010525050A5 (enExample) | ||
| JP2009507838A5 (enExample) | ||
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| KR20110045065A (ko) | 월경 억제, 피임 및 호르몬 대체 요법을 위한 약제 및 이를 투여하는 방법 | |
| HUP0105173A2 (hu) | Adagolási módszer és készítmény sürgősségi fogamzásgátlásra | |
| JP2021520400A (ja) | エダラボン医薬組成物 | |
| CN107519159A (zh) | 复方组合物 | |
| JP2024164177A (ja) | 疣贅の治療 | |
| JPS59112948A (ja) | コレステロ−ルレベル低下剤 | |
| JP2009506978A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2025520237A5 (ja) | 哺乳動物の非結核性マイコバクテリア感染症治療薬 | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| CN117396198A (zh) | 改善和预防年龄相关性肌肉退化的方法 | |
| JP2025098147A5 (enExample) | ||
| CN104758304B (zh) | 三七皂苷r1的医药用途 | |
| CA2504665A1 (en) | Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia | |
| US20240009154A1 (en) | Methods and compositions for treating cytokine release syndrome | |
| JP2835123B2 (ja) | ペンタミジン溶液 | |
| JPH027293B2 (enExample) |